...
首页> 外文期刊>Infection and immunity >Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine
【24h】

Randomized, Controlled Human Challenge Study of the Safety, Immunogenicity, and Protective Efficacy of a Single Dose of Peru-15, a Live Attenuated Oral Cholera Vaccine

机译:口服减毒霍乱疫苗Peru-15的单剂量安全性,免疫原性和保护功效的随机对照人类挑战研究

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Peru-15 is a live attenuated oral vaccine derived from a Vibrio cholerae O1 El Tor Inaba strain by a series of deletions and modifications, including deletion of the entire CT genetic element. Peru-15 is also a stable, motility-defective strain and is unable to recombine with homologous DNA. We wished to determine whether a single oral dose of Peru-15 was safe and immunogenic and whether it would provide significant protection against moderate and severe diarrhea in a randomized, double-blind, placebo-controlled human volunteer cholera challenge model. A total of 59 volunteers were randomly allocated to groups to receive either 2 × 108 CFU of reconstituted, lyophilized Peru-15 vaccine diluted in CeraVacx buffer or placebo (CeraVacx buffer alone). Approximately 3 months after vaccination, 36 of these volunteers were challenged with approximately 105 CFU of virulent V. cholerae O1 El Tor Inaba strain N16961, prepared from a standardized frozen inoculum. Among vaccinees, 98% showed at least a fourfold increase in vibriocidal antibody titers. After challenge, 5 (42%) of the 12 placebo recipients and none (0%) of the 24 vaccinees had moderate or severe diarrhea (≥3,000 g of diarrheal stool) (P = 0.002; protective efficacy, 100%; lower one-sided 95% confidence limit, 75%). A total of 7 (58%) of the 12 placebo recipients and 1 (4%) of the 24 vaccinees had any diarrhea (P < 0.001; protective efficacy, 93%; lower one-sided 95% confidence limit, 62%). The total number of diarrheal stools, weight of diarrheal stools, incidence of fever, and peak stool V. cholerae excretion among vaccinees were all significantly lower than in placebo recipients. Peru-15 is a well-tolerated and immunogenic oral cholera vaccine that affords protective efficacy against life-threatening cholera diarrhea in a human volunteer challenge model. This vaccine may therefore be a safe and effective tool to prevent cholera in travelers and is a strong candidate for further evaluation to prevent cholera in an area where cholera is endemic.
机译:Peru-15是一种减毒活疫苗,源自霍乱弧菌O1 El Tor Inaba毒株,通过一系列缺失和修饰,包括整个CT遗传元件的缺失。 Peru-15也是一种稳定的,具有运动能力的品系,无法与同源DNA重组。我们希望确定在随机,双盲,安慰剂对照的人类自愿霍乱挑战模型中,单次口服Peru-15的剂量是否安全且具有免疫原性,以及是否能为中度和重度腹泻提供显着保护。总共59名志愿者被随机分配到各组,接受2×10 8 CFU的重组冻干的Peru-15疫苗稀释,稀释于CeraVacx缓冲液或安慰剂(单独使用CeraVacx缓冲液)中。接种疫苗约3个月后,其中36名志愿者接受了约10 5 CFU的强毒 V攻击。由标准的冷冻接种物制备的霍乱弧菌O1 El Tor Inaba菌株N16961。在疫苗接种者中,98%的杀螨抗体滴度至少增加了四倍。攻击后,在12名安慰剂接受者中有5名(42%),在24种疫苗接种者中没有(0%)有中度或重度腹泻(≥3,000 g腹泻大便)( P = 0.002;保护效力,100%;降低单边95%置信度上限(75%)。 12名安慰剂接受者中有7名(58%)和24种疫苗接种者中有1名(4%)有腹泻( P <0.001;保护功效为93%;单侧较低的为95%置信度限制为62%)。腹泻粪便的总数,腹泻粪便的重量,发烧的发生率和大便 V。疫苗接种者中霍乱的排泄率均显着低于安慰剂接受者。 Peru-15是一种耐受性良好且具有免疫原性的口服霍乱疫苗,可在人类志愿者挑战模型中提供针对威胁生命的霍乱腹泻的保护性功效。因此,该疫苗可能是预防旅行者霍乱的安全有效工具,并且是进一步评估霍乱流行地区霍乱的强有力候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号